Maplight Therapeutics (MPLT) Competitors

$26.96 +0.46 (+1.72%)

As of 02:50 PM Eastern

MPLT vs. GRFS, APGE, CRSP, DNTH, and INDV

Should you buy Maplight Therapeutics stock or one of its competitors? MarketBeat compares Maplight Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Maplight Therapeutics include Grifols (GRFS), Apogee Therapeutics (APGE), CRISPR Therapeutics (CRSP), Dianthus Therapeutics (DNTH), and Indivior (INDV). These companies are all part of the "pharmaceutical products" industry.

How does Maplight Therapeutics compare to Grifols?

Maplight Therapeutics (NASDAQ:MPLT) and Grifols (NASDAQ:GRFS) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Grifols has higher revenue and earnings than Maplight Therapeutics. Maplight Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$39.65	N/A
Grifols	$8.51B	0.63	$454.82M	$0.19	41.45

Grifols has a net margin of 5.54% compared to Maplight Therapeutics' net margin of 0.00%. Grifols' return on equity of 6.21% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Grifols	5.54%	6.21%	2.39%

Maplight Therapeutics presently has a consensus price target of $34.43, indicating a potential upside of 27.72%. Grifols has a consensus price target of $10.00, indicating a potential upside of 26.98%. Given Maplight Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Maplight Therapeutics is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Maplight Therapeutics had 15 more articles in the media than Grifols. MarketBeat recorded 17 mentions for Maplight Therapeutics and 2 mentions for Grifols. Maplight Therapeutics' average media sentiment score of 0.05 beat Grifols' score of -0.17 indicating that Maplight Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grifols	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Grifols beats Maplight Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Maplight Therapeutics compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Maplight Therapeutics (NASDAQ:MPLT) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Maplight Therapeutics had 14 more articles in the media than Apogee Therapeutics. MarketBeat recorded 17 mentions for Maplight Therapeutics and 3 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.18 beat Maplight Therapeutics' score of 0.05 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Apogee Therapeutics presently has a consensus target price of $112.73, suggesting a potential upside of 45.07%. Maplight Therapeutics has a consensus target price of $34.43, suggesting a potential upside of 27.72%. Given Apogee Therapeutics' higher probable upside, equities analysts plainly believe Apogee Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.78
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$39.65	N/A

79.0% of Apogee Therapeutics shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Maplight Therapeutics' return on equity of 0.00% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Maplight Therapeutics	N/A	N/A	N/A

Summary

Apogee Therapeutics and Maplight Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Maplight Therapeutics compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Maplight Therapeutics (NASDAQ:MPLT) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Maplight Therapeutics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,302.76	-$581.60M	-$6.22	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$39.65	N/A

69.2% of CRISPR Therapeutics shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Maplight Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. Maplight Therapeutics' return on equity of 0.00% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Maplight Therapeutics	N/A	N/A	N/A

In the previous week, Maplight Therapeutics had 11 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 17 mentions for Maplight Therapeutics and 6 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.66 beat Maplight Therapeutics' score of 0.05 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CRISPR Therapeutics presently has a consensus price target of $65.47, suggesting a potential upside of 38.09%. Maplight Therapeutics has a consensus price target of $34.43, suggesting a potential upside of 27.72%. Given CRISPR Therapeutics' higher possible upside, research analysts clearly believe CRISPR Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Summary

Maplight Therapeutics beats CRISPR Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Maplight Therapeutics compare to Dianthus Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Dianthus Therapeutics (NASDAQ:DNTH) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Maplight Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -12,998.50%. Maplight Therapeutics' return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

In the previous week, Maplight Therapeutics had 13 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 17 mentions for Maplight Therapeutics and 4 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.33 beat Maplight Therapeutics' score of 0.05 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dianthus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maplight Therapeutics has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$39.65	N/A
Dianthus Therapeutics	$2.04M	2,296.86	-$162.34M	-$4.13	N/A

47.5% of Dianthus Therapeutics shares are held by institutional investors. 3.8% of Maplight Therapeutics shares are held by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Maplight Therapeutics presently has a consensus target price of $34.43, indicating a potential upside of 27.72%. Dianthus Therapeutics has a consensus target price of $117.82, indicating a potential upside of 37.47%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dianthus Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Maplight Therapeutics and Dianthus Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Maplight Therapeutics compare to Indivior?

Indivior (NASDAQ:INDV) and Maplight Therapeutics (NASDAQ:MPLT) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

60.3% of Indivior shares are held by institutional investors. 0.7% of Indivior shares are held by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Indivior has higher revenue and earnings than Maplight Therapeutics. Maplight Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.29B	3.52	$210M	$1.95	19.12
Maplight Therapeutics	N/A	N/A	-$161.15M	-$39.65	N/A

Indivior has a net margin of 19.44% compared to Maplight Therapeutics' net margin of 0.00%. Maplight Therapeutics' return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Maplight Therapeutics	N/A	N/A	N/A

In the previous week, Maplight Therapeutics had 15 more articles in the media than Indivior. MarketBeat recorded 17 mentions for Maplight Therapeutics and 2 mentions for Indivior. Indivior's average media sentiment score of 0.33 beat Maplight Therapeutics' score of 0.05 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Indivior currently has a consensus price target of $39.33, indicating a potential upside of 5.51%. Maplight Therapeutics has a consensus price target of $34.43, indicating a potential upside of 27.72%. Given Maplight Therapeutics' higher possible upside, analysts plainly believe Maplight Therapeutics is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Summary

Indivior beats Maplight Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Maplight Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MPLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MPLT vs. The Competition

Export

Metric	Maplight Therapeutics	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.15B	$2.91B	$4.16B	$12.15B
Dividend Yield	N/A	15.25%	6.12%	5.32%
P/E Ratio	-0.68	12.97	22.66	25.14
Price / Sales	N/A	1,938.16	118.31	91.94
Price / Cash	N/A	26.32	50.53	37.30
Price / Book	2.67	6.11	38.61	6.65
Net Income	-$161.15M	-$42.05M	$113.56M	$335.51M
7 Day Performance	-11.03%	-0.94%	-0.28%	-1.56%
1 Month Performance	-10.29%	0.20%	-0.29%	-1.44%
1 Year Performance	N/A	15.41%	13.95%	28.08%

Maplight Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MPLT Maplight Therapeutics	3.0306 of 5 stars	$26.96 +1.7%	$34.43 +27.7%	N/A	$1.15B	N/A	N/A	109	Earnings Report Insider Trade Analyst Revision
GRFS Grifols	4.2571 of 5 stars	$7.71 +2.0%	$10.00 +29.7%	+1.4%	$5.15B	$7.52B	40.58	25,247	Analyst Downgrade
APGE Apogee Therapeutics	2.4845 of 5 stars	$83.94 +1.2%	$112.73 +34.3%	+93.9%	$5.13B	N/A	N/A	91
CRSP CRISPR Therapeutics	3.2381 of 5 stars	$52.75 -0.2%	$65.47 +24.1%	+25.3%	$5.10B	$3.51M	N/A	460
DNTH Dianthus Therapeutics	2.5781 of 5 stars	$85.74 -0.5%	$117.82 +37.4%	+324.6%	$4.71B	$2.04M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MPLT) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maplight Therapeutics (MPLT) Competitors

MPLT vs. GRFS, APGE, CRSP, DNTH, and INDV

How does Maplight Therapeutics compare to Grifols?

Summary

How does Maplight Therapeutics compare to Apogee Therapeutics?

Summary

How does Maplight Therapeutics compare to CRISPR Therapeutics?

Summary

How does Maplight Therapeutics compare to Dianthus Therapeutics?

Summary

How does Maplight Therapeutics compare to Indivior?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MPLT vs. The Competition

Maplight Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maplight Therapeutics (MPLT) Competitors

MPLT vs. GRFS, APGE, CRSP, DNTH, and INDV

How does Maplight Therapeutics compare to Grifols?

Which has better valuation and earnings, MPLT or GRFS?

Is MPLT or GRFS more profitable?

Do analysts prefer MPLT or GRFS?

Does the media prefer MPLT or GRFS?

Summary

How does Maplight Therapeutics compare to Apogee Therapeutics?

Does the media prefer APGE or MPLT?

Do analysts recommend APGE or MPLT?

Which has preferable earnings and valuation, APGE or MPLT?

Do institutionals and insiders have more ownership in APGE or MPLT?

Is APGE or MPLT more profitable?

Summary

How does Maplight Therapeutics compare to CRISPR Therapeutics?

Which has better earnings and valuation, CRSP or MPLT?

Do insiders and institutionals have more ownership in CRSP or MPLT?

Is CRSP or MPLT more profitable?

Does the media prefer CRSP or MPLT?

Do analysts prefer CRSP or MPLT?

Summary

How does Maplight Therapeutics compare to Dianthus Therapeutics?

Is MPLT or DNTH more profitable?

Does the media prefer MPLT or DNTH?

Which has stronger earnings & valuation, MPLT or DNTH?

Do institutionals & insiders hold more shares of MPLT or DNTH?

Do analysts rate MPLT or DNTH?

Summary

How does Maplight Therapeutics compare to Indivior?

Do institutionals and insiders hold more shares of INDV or MPLT?

Which has better valuation & earnings, INDV or MPLT?

Is INDV or MPLT more profitable?

Does the media prefer INDV or MPLT?

Do analysts rate INDV or MPLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MPLT vs. The Competition

Maplight Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools